[Special Stock] Boryung, Vibozon Obtain Approval for 'Onapraju'... Highlighted Commercialization Cooperation

Boryung is on the rise. The news that Vibozone Pharmaceutical has obtained product approval from the Ministry of Food and Drug Safety for the non-narcotic analgesic Onapraju (generic name Opiranzerin) appears to have had an impact. Boryung has previously signed a memorandum of understanding (MOU) with the Vibozone Group for the domestic commercialization of 'Onapraju.'

As of 9:23 AM on the 13th, Boryung was trading at 10,230 KRW, up 420 KRW (4.28%) from the previous trading day.

Boryung signed an MOU for domestic commercialization with the Vibozone Group in April this year. The Vibozone Group stated that after receiving approval for Onapraju from the Ministry of Food and Drug Safety, it plans to provide the finished product to Boryung and share roles in distribution and sales.

Onapraju, a drug discovered through multi-target new drug development platform technology, is the world's first non-narcotic, non-anti-inflammatory analgesic. It works by simultaneously inhibiting Glycine Transporter 2 (GlyT2) and Serotonin Receptor 2a (5HT2a), blocking pain signals and transmission occurring in multiple sites within the central and peripheral nervous systems.

Previously, Vibozone Pharmaceutical secured statistical significance for efficacy in domestic Phase 3 clinical trials and applied for product approval from the Ministry of Food and Drug Safety in November last year. Efficacy was confirmed through the primary endpoint 'Sum of Pain Intensity Difference over 12 hours (SPID 12)' and secondary endpoints 'Number of Patient-Controlled Analgesia (PCA) requests over 12 hours' and 'Consumption of PCA and rescue medication over 12 hours.'

This approval is expected to bring revolutionary changes to the market for moderate or higher pain treatments, where there are no alternatives other than narcotic analgesics and unmet medical needs are high. From the clinical stage, Onapraju has been evaluated as a 'game changer' in the medical community due to its lower side effects and no addiction risk compared to narcotic analgesics, while demonstrating rapid analgesic effects.

This content was produced with the assistance of AI translation services.